| Code | CSB-RA011591MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to eblasakimab, targeting interleukin-13 receptor alpha 1 (IL13RA1). IL13RA1 serves as a receptor subunit for interleukin-13, a key cytokic involved in type 2 immune responses and allergic inflammation. This receptor mediates IL-13 signaling pathways that regulate IgE production, mucus secretion, and airway hyperresponsiveness. Dysregulated IL13RA1 expression and signaling are implicated in various pathological conditions, including asthma, atopic dermatitis, chronic obstructive pulmonary disease, and certain malignancies where it contributes to tumor progression and therapeutic resistance.
Eblasakimab represents a therapeutic antibody developed to modulate IL-13 signaling through IL13RA1 blockade, with clinical investigation in inflammatory and allergic disorders. This biosimilar antibody provides researchers with a valuable tool for investigating IL-13/IL13RA1 pathway mechanisms, exploring therapeutic intervention strategies, and studying receptor-mediated immune responses in preclinical models. It supports diverse research applications in immunology, respiratory disease, dermatology, and oncology.
There are currently no reviews for this product.